ダウンロード数: 646
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
57_487.pdf | 631.06 kB | Adobe PDF | 見る/開く |
タイトル: | 難治性セミノーマの臨床的検討 |
その他のタイトル: | Clinical Outcome of Refractory Seminoma |
著者: | 前鼻, 健志 田中, 俊明 北村, 寛 舛森, 直哉 塚本, 泰司 |
著者名の別形: | Maehana, Takeshi Tanaka, Toshiaki Kitamura, Hiroshi Masumori, Naoya Tsukamoto, Taiji |
キーワード: | Germ cell tumor Seminoma Chemotherapy Refractory |
発行日: | Sep-2011 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 57 |
号: | 9 |
開始ページ: | 487 |
終了ページ: | 490 |
抄録: | We retrospectively reviewed 67 patients with pure seminoma who were treated in our hospital between 1991 and 2009. Fifteen (22.4%) patients had metastatic or recurrent disease and underwent chemotherapy. Induction chemotherapy provided freedom from disease with no recurrence in 9 patients. On the other hand, 6 patients had chemotherapy-resistant seminoma (refractory group). We herein report the clinical features of the refractory group. Although we could not determine the risk factors for refractory disease, clinical stage III disease was resistant to induction chemotherapy. The refractory group consisted of 2 patients with recurrent disease after prophylactic radiation therapy for stage I disease, 1 with stage IIB and 3 with stage IIIC disease. In the refractory group, 3 patients obtained freedom from disease after additional chemotherapy with salvage surgery. However, 3 patients died from cancer in spite of multiple salvage treatments. Salvage radiation therapy was performed for inoperable metastatic disease in 3 patients and might have contributed to disease control in 2 patients. Some patients with pure seminoma can develop refractory disease, although the prediction is difficult. Multimodality therapy including salvage radiation possibly provides survival benefit. |
著作権等: | 許諾条件により本文は2012-10-01に公開 |
URI: | http://hdl.handle.net/2433/149239 |
PubMed ID: | 22075608 |
出現コレクション: | Vol.57 No.9 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。